Tirzepatide as Compared with Semaglutide for the Treatment of Obesity
Open accessThe DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Tirzepatide and semaglutide are highly effective medications for obesity management. The efficacy and safety of tirzepatide as compared with semaglutide in adults with obesity but without type 2 diabetes is unknown. METHODS: In this phase 3b, open-label, controlled trial, adult participants with obesity but without type 2 diabetes were randomly assigned in a 1:1 ratio to receive the maximum tolerated dose of tirzepatide (10 mg or 15 mg) or the maximum tolerated dose of semaglutide (1.7 mg or 2.4 mg) subcutaneously once weekly for 72 weeks. The primary end point was the percent change in weight from baseline to week 72. Key secondary end points included weight reductions of at least 10%, 15%, 20%, and 25% and a change in waist circumference from baseline to week 72. RESULTS: A total of 751 participants underwent randomization. The least-squares mean percent change in weight at week 72 was -20.2% (95% confidence interval [CI], -21.4 to -19.1) with tirzepatide and -13.7% (95% CI, -14.9 to -12.6) with semaglutide (P<0.001). The least-squares mean change in waist circumference was -18.4 cm (95% CI, -19.6 to -17.2) with tirzepatide and -13.0 cm (95% CI, -14.3 to -11.7) with semaglutide (P<0.001). Participants in the tirzepatide group were more likely than those in the semaglutide group to have weight reductions of at least 10%, 15%, 20%, and 25%. The most common adverse events in both treatment groups were gastrointestinal, and most were mild to moderate in severity and occurred primarily during dose escalation. CONCLUSIONS: Among participants with obesity but without diabetes, treatment with tirzepatide was superior to treatment with semaglutide with respect to reduction in body weight and waist circumference at week 72. (Funded by Eli Lilly; SURMOUNT-5 ClinicalTrials.gov number, NCT05822830.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Tirzepatide also leads to greater weight loss than semaglutide for people with type 2 diabetes 14 and than liraglutide for people with obesity.15”
From GLP-1 receptor agonists and next-generation incretin-based medications: metabolic, cardiovascular, and renal benefits (2026) · cites this paper as [15]
In the citing paper
“In the STEP-8 trial, 70 semaglutide 2•4 mg/week led to greater weight loss (a 15•8% reduction) compared with liraglutide 3•0 mg once daily (a 6•4% reduction); in the SURMOUNT-5 trial, 15 tirzepatide 15 mg caused significantly higher weight reduction (20•2%) compared with semaglutide 2•4 mg (13•7%”
From GLP-1 receptor agonists and next-generation incretin-based medications: metabolic, cardiovascular, and renal benefits (2026) · cites this paper as [15]
In the citing paper
“in the SURMOUNT-5 trial, 15 tirzepatide 15 mg caused significantly higher weight reduction (20•2%) compared with semaglutide 2•4 mg (13•7% )”
From GLP-1 receptor agonists and next-generation incretin-based medications: metabolic, cardiovascular, and renal benefits (2026) · cites this paper as [15]
In the citing paper
“Similar differences in effectiveness are found when looking at reductions in waist circumference, systolic blood pressure, and serum triglycerides, with differences in effect sizes reflecting the differences in weight loss in response to liraglutide, semaglutide, and tirzepatide treatment.15,70”
From GLP-1 receptor agonists and next-generation incretin-based medications: metabolic, cardiovascular, and renal benefits (2026) · cites this paper as [15]
In the citing paper
“The efficacy of GLP-1 receptor agonists (GLP-1 RAs) in older adults has been robustly demonstrated in randomized controlled trials (RCTs) [34], providing strong evidence for their use in managing obesity and related comorbidities in individuals aged over 65.”
From A Narrative Review on GLP-1 Receptor Agonists for Obesity in Older Women: Maximizing Weight Loss While Preserving Lean Mass (2026) · cites this paper as [34]
15 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
(1998) · PsycEXTRA Dataset · doi:10.1037/e565682010-001 · Cited by 9,472
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2032183 · Cited by 5,205
Tirzepatide Once Weekly for the Treatment of Obesity
Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., Kiyosue, A., Zhang, S., Liu, B., Bunck, M. C., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2206038 · Cited by 3,838
Self-citationSemaglutide and Cardiovascular Outcomes in Obesity without Diabetes
Lincoff, A. M., Brown-Frandsen, K., Colhoun, H. M., Deanfield, J., Emerson, S. S., Esbjerg, S., Hardt-Lindberg, S., Hovingh, G. K., Kahn, S. E., Kushner, R. F., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2307563 · Cited by 3,236
Jensen, M. D., Ryan, D. H., Apovian, C. M., Ard, J. D., Comuzzie, A. G., Donato, K. A., Hu, F. B., Hubbard, V. S., Jakicic, J. M., Kushner, R. F., et al. (2014) · Circulation · doi:10.1161/01.cir.0000437739.71477.ee · Cited by 2,735
Garvey, W. T., Mechanick, J. I., Brett, E. M., Garber, A. J., Hurley, D. L., Jastreboff, A. M., Nadolsky, K., Pessah-Pollack, R., & Plodkowski, R. (2016) · Endocrine Practice · doi:10.4158/ep161365.gl · Cited by 1,914
Whelton, P. K. (2002) · JAMA · doi:10.1001/jama.288.15.1882 · Cited by 1,473
Coskun, T., Sloop, K. W., Loghin, C., Alsina-Fernandez, J., Urva, S., Bokvist, K. B., Cui, X., Briere, D. A., Cabrera, O., Roell, W. C., et al. (2018) · Molecular Metabolism · doi:10.1016/j.molmet.2018.09.009 · Cited by 882
Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity
Malhotra, A., Grunstein, R. R., Fietze, I., Weaver, T. E., Redline, S., Azarbarzin, A., Sands, S. A., Schwab, R. J., Dunn, J. P., Chakladar, S., et al. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2404881 · Cited by 871
Self-citationTwo-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial
Garvey, W. T., Batterham, R. L., Bhatta, M., Buscemi, S., Christensen, L. N., Frias, J. P., Jódar, E., Kandler, K., Rigas, G., Wadden, T. A., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-02026-4 · Cited by 868
Cited by
Items 201–300 of 590
Taha, M. M. E., Abdelwahab, S. İ., Oraibi, O., Madkhali, M. A., Alhazmi, A., Jeraiby, M., Abdullah, S. M., Farasani, A. M., Moshi, J. M., Khamjan, N. A., et al. (2025) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-025-04574-1 · Cited by 3
Sun, X., Yin, Y., Song, M., Droz, B. A., LIN, Y., Beaty, K. N., Zhou, B., Roh, H. C., Wilson, J. M., Cain, P., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2025.12.18.695152 · Cited by 2
Alfaris, N., Kushner, R. F., Li, J., Chen, K. L., Fenimore, M., Calderón, B., & Stefański, A. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70991 · Cited by 3
Jennings, I., Ly, K., Marooki, M., Dzotsi, M., McLaren, G., Cuomo, R. E., Abohashem, S., & Taub, P. R. (2026) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwag279 · Cited by 2
Gunasekaran, P., Inban, P., Agrawal, A., Thai, A., Aravazhi, P. S., Tariq, H., Prajjwal, P., & John, J. (2026) · Disease-a-Month · doi:10.1016/j.disamonth.2026.102113 · Cited by 3
Camilleri, M. (2026) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2026.03.038 · Cited by 3
Trott, M., Arnautovska, U., Johnston, D. J. G., Ritchie, G., & Siskind, D. J. (2026) · BJPsych Open · doi:10.1192/bjo.2026.12001 · Cited by 3
Aghemo, A., Armandi, A., Bugianesi, E., Cabibbo, G., Carbone, M., D’Ambrosio, R., Dalbeni, A., Cola, S. D., Gasbarrini, A., Germani, G., et al. (2026) · Digestive and Liver Disease · doi:10.1016/j.dld.2026.02.014 · Cited by 4
GLP-1 and GIP agonists in diabetes and obesity and the rise of dyspepsia
Masulli, M., Tack, J. F., Esposito, G., & Sarnelli, G. (2025) · Internal and Emergency Medicine · doi:10.1007/s11739-025-04117-9 · Cited by 3
Obesity and gastrointestinal cancer: A converging epidemic with surgical consequence
Gosavi, R., Jaya, J. S., Yap, R. J., Narasimhan, V., & Ooi, G. (2025) · European Journal of Surgical Oncology · doi:10.1016/j.ejso.2025.110358 · Cited by 3
Management of obesity in advanced chronic liver disease
Caussy, C., & Francque, S. (2026) · JHEP Reports · doi:10.1016/j.jhepr.2026.101749 · Cited by 3
Papantoniou, P., & Maniadakis, N. (2025) · Healthcare · doi:10.3390/healthcare13162011 · Cited by 4
GLP-1 Receptor Agonists vs Alternatives for Alcohol Use Disorder: A Multi-Target Trial EmulationPreprint
Rodriguez, P. J., Lusk, J. B., Mehta, H. B., Levy, J. F., Kalogeropoulos, A. P., Soneji, S. S., Webber, E., Gluckman, T. J., & Stucky, N. L. (2025) · medRxiv · doi:10.1101/2025.06.07.25329184 · Cited by 2
Time-to-First Clinical Benefit of Glucagon-Like Peptide-1 Receptor Agonists in Heart Failure
Basile, C., Merolla, A., Mancusi, C., Ambrosino, P., LORENZO, R. D., Rovere, P. Q., & Maggioni, A. P. (2025) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2025.11.489 · Cited by 1
Belančić, A., Radić, M., Pavlović, M. R., Vučković, M., Šimac, P., Gkrinia, E. M. M., Radić, J., & Fajkić, A. (2026) · Metabolites · doi:10.3390/metabo16050347 · Cited by 1
Sacks, G. I., Meydan, Y., Lebens, R. S., & Mushlin, H. M. (2026) · European Spine Journal · doi:10.1007/s00586-026-10099-9 · Cited by 2
Maradia, J., Joshi, S. S., Koli, P. G., Radhakrishnan, M., & Athavale, C. (2026) · Tzu Chi Medical Journal · doi:10.4103/tcmj.tcmj-d-25-00078 · Cited by 1
Glucagon-like peptide-1–based pharmacological treatment of obesity: a narrative review
Son, J. W. (2026) · Journal of Korean Medical Association · doi:10.5124/jkma.25.0138 · Cited by 1
Ciudin, A., Baker, J. L., Belančić, A., Busetto, L., Diker, D., Fábryová, Ľ., Frühbeck, G., Goossens, G. H., Gordon, J., Monami, M., et al. (2026) · medRxiv · doi:10.64898/2026.04.19.26351196 · Cited by 1
Ali, S. H., Lee, M. K., Tan, X. Q., Wong, C. J., Magkos, F., Ang, I. Y. H., & Toh, S.-A. E. S. (2026) · International Journal of Obesity · doi:10.1038/s41366-026-02062-x · Cited by 2
Malik, F., Shah, M., Chang, Y. K., Chowdhury, I. Z., Mangalesh, S., Morgan, A. A., Ezerioha, P., Modak, V., Lebovics, N., Adhikari, S., et al. (2026) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvag044 · Cited by 2
Beyond GLP‐1: The Cardiometabolic Potential of Dual GLP‐1/GIP Receptor Agonists
Xue, C. (2026) · iNew Medicine · doi:10.1002/inm3.70048 · Cited by 2
Harbi, M. H., Ashour, A. M., Alorfi, N. M., Aldurdunji, M. M., Wali, S. M., & Alzahrani, Y. A. (2026) · Frontiers in Medicine · doi:10.3389/fmed.2026.1764664 · Cited by 4
Distinct brain regions mediate regulation of food intake in response to GIPR agonism or antagonism
Lewis, J. E., Montaner, M., Nuzzaci, D., James-Okoro, P.-P., Harada, N., Inagaki, N., Dodson, W. S., Knerr, P. J., Douros, J. D., Gribble, F. M., et al. (2026) · Nature Metabolism · doi:10.1038/s42255-026-01575-z · Cited by 6
ForePass outperforms Semaglutide in weight control, glucose metabolism, and gut microbiota in swine
Russo, S. L. M. L., Proto, L., Neto, M. G., Angelini, G., Pezzica, S., Carli, F., Previti, E., Caristo, M. E., Bove, V., Chakaroun, R., et al. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70167 · Cited by 3
Falahee, B. E., Apovian, C. M., & Istfan, N. W. (2026) · Obesity · doi:10.1002/oby.70294 · Cited by 2
Obesity management medications for the surgeon
Harris, M., Mahdi, S., Fairfield, C. J., Brown, L. R., Wadley, M., & Miras, A. D. (2026) · Frontline Gastroenterology · doi:10.1136/flgastro-2025-103307 · Cited by 1
Childhood obesity and cardiac risk in youth: Emerging challenges toward 2050
Mishra, N. K. (2026) · Clinical Nutrition ESPEN · doi:10.1016/j.clnesp.2026.103260 · Cited by 2
Saeed, Z. I., & Apovian, C. M. (2025) · Current Atherosclerosis Reports · doi:10.1007/s11883-025-01369-w · Cited by 2
Position Statement on Cardiometabolic Health Across the Woman's Life Course – 2025
de Oliveira, G. M. M., de Almeida, M. C. C., Valério, C. M., Giuffrida, F. M. A., Espíndola, L. N., Izar, M. C. D. O., Marques-Santos, C., Freire, C. M. V., Albuquerque, C. J. D. M., Chagas, A. C. P., et al. (2025) · Arquivos Brasileiros de Cardiologia · doi:10.36660/abc.20250615i · Cited by 2
Tirzepatide and the risk of atherosclerotic cardiovascular events: population based cohort study
Krüger, N., Schneeweiß, S., & Wang, S. V. (2026) · BMJ · doi:10.1136/bmj-2026-100011 · Cited by 2
McElroy, J. A., Bertarelli, I., Maltagliati, C., Smith, J., & DePietro, R. (2026) · Obesity · doi:10.1002/oby.70275 · Cited by 1
Shirley, M. (2026) · Drugs · doi:10.1007/s40265-026-02363-5 · Cited by 3
TIRZEPATIDA E ESTÉTICA CORPORAL: POTENCIAL TERAPEUTICO NO EMAGRECIMENTO E SEUS EFEITOS ADVERSOS
de Gois, N. P., Mora, R., de Mendonça, G. J. G., Clavijo, B., do Nascimento, S. B., Carneiro, F. F., Scalabrini, E. B., Shibata, C., & Pessôa, F. S. (2025) · Revista Contemporânea · doi:10.56083/rcv5n7-144 · Cited by 8
Real‐World Weight‐Loss Outcomes in Weight‐Reduced Patients Treated With Tirzepatide
Barenbaum, S. R., Gonzalez, A., Verzani, Z., Zhao, A. S., & Shukla, A. P. (2026) · Obesity · doi:10.1002/oby.70179 · Cited by 3
Mushtaq, M. N., Hamid, M., Rahman, A., Javed, F., Issa, M. T., Naqvi, M., Kabir, S. A., Mirza, S., Khan, A. U., & Karim, M. (2026) · Obesity Surgery · doi:10.1007/s11695-026-08525-4 · Cited by 1
Zhu, Z.-N., You, C., Yuan, Q., Xu, J.-Y., Gu, Z.-Y., Huang, Z., Liu, M., Shan, B., Wang, J. J., Hu, W., et al. (2026) · Acta Pharmacologica Sinica · doi:10.1038/s41401-025-01720-6 · Cited by 2
Kasagga, A., Rebellow, D., Hashmi, T., Husami, M. Y., Lama, P., Selvan, K., & Nakasagga, K. (2025) · Cureus · doi:10.7759/cureus.90335 · Cited by 13
Katsura, M., Horiuchi, Y., Tanabe, K., & Wettersten, N. W. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70721 · Cited by 1
de Roos, B. M., Monpellier, V. M., Hansen, D., Eijsvogels, T. M. H., Thijssen, D. H. J., & Karregat, J. H. M. (2026) · Netherlands Heart Journal · doi:10.1007/s12471-026-02076-0 · Cited by 1
Acute onset of neovascular age-related macular degeneration after initiation of tirzepatide
Takebayashi, K., Iemura, Y., Yamauchi, M., Hara, K., Tsuchiya, T., Machida, S., & Hashimoto, K. (2026) · Diabetology International · doi:10.1007/s13340-026-00885-7 · Cited by 1
Liver–pancreas communication in disease and drug development
Jia, Y., Zhu, Q., Pan, Q., Lu, G., & Xiao, J. (2026) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2026.01.018 · Cited by 3
Zickler, C. L., Alfonsi, S. P., Shalakthi, O. S., Alli, N. K., Acuña, A. J., Forlenza, E. M., Terhune, E. B., & Burnett, R. A. (2026) · Knee Surgery Sports Traumatology Arthroscopy · doi:10.1002/ksa.70473 · Cited by 1
Managing Obesity in Individuals with Cardiovascular Disease: Are We Missing the Obvious?
Gao, M., Kurala, T. S., & Ajjan, R. (2026) · European Cardiology Review · doi:10.15420/ecr.2025.53 · Cited by 1
Lee, S., Kim, H. C., Yoon, Y., Jang, I., Yoo, S., & Yu, K. (2025) · British Journal of Clinical Pharmacology · doi:10.1002/bcp.70311 · Cited by 2
Self-reported side effects of semaglutide and tirzepatide in online communities
Sehgal, N. K. R., Tronieri, J. S., Ungar, L., & Guntuku, S. C. (2026) · Nature Health · doi:10.1038/s44360-026-00108-y · Cited by 11
The case for primary prevention of obesity in the era of GLP-1 therapies
Holm, S., Tena‐Sempere, M., Koutsouris, D., Dedoussis, G. V., Wagner, K., Martinez, S. A., Froguel, P., Bohn, T., Oliveira, P. J., Lakerveld, J., et al. (2026) · The Lancet Regional Health - Europe · doi:10.1016/j.lanepe.2026.101679 · Cited by 1
Henriques, J. P., Weckwerth, A. V. B., Sant’Ana, A. C. P., Damante, C. A., Santos, C. F., & Negrato, C. A. (2026) · Annales Pharmaceutiques Françaises · doi:10.1016/j.pharma.2026.06.008 · Cited by 5
Molecular, genetic, and pharmacological advances in type 2 diabetes (2015–2025)
Romero, R. C. (2026) · BioMolecular Concepts · doi:10.1515/bmc-2025-0059 · Cited by 1
Tirzepatide in Metabolic Diseases: Clinical Efficacy and Safety Beyond Diabetes and Obesity
Dong, S., Xu, Y., Gan, R., Zhang, A., He, J., & Tang, Q. (2026) · Medicinal Research Reviews · doi:10.1002/med.70049 · Cited by 1
The association of obesity with cardiovascular disease risk and risk-enhancing factors
Paparodis, R. D., Bantouna, D., Livadas, S., & Angelopoulos, N. (2026) · Journal of clinical lipidology · doi:10.1016/j.jacl.2025.08.018 · Cited by 6
Obesity in children and adolescents
Berman, C., Kohn, B., & Wilson, D. P. (2026) · Journal of clinical lipidology · doi:10.1016/j.jacl.2025.07.004 · Cited by 7
Geagea, M., Kozaily, E., Buchanan, C. J., Litwin, S. E., & Tedford, R. J. (2026) · Heart Failure Reviews · doi:10.1007/s10741-026-10601-x · Cited by 1
Silva, J. P. M. R. J., Nogueira, B., Sartori, D. L., da Silva, J. A. R., Sciota, L. B. A., Bisneto, O. I. D. M., & Gomes, W. F. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.71051 · Cited by 2
Nguyen, T., Hong, L., & Iso, T. (2026) · Cardiorenal Medicine · doi:10.1159/000552517 · Cited by 1
Agha, A., Afandi, B. O., Alhammadi, W. I., Almaskari, H. J. M., Alshamsi, A., Saleem, M., & Kaabi, J. A. (2025) · Obesity Medicine · doi:10.1016/j.obmed.2025.100656 · Cited by 6
Are Glucagon-Like Peptide 1 Receptor Agonists and Bariatric Surgery the Answer to Childhood Obesity?
Kumar, S., Olson, O., & Kellogg, T. A. (2025) · Current Atherosclerosis Reports · doi:10.1007/s11883-025-01347-2 · Cited by 3
Xiao-yu, Z., Deng, C.-H., Zhong, J.-Y., Wu, Q., Chen, Q.-X., Gao, X.-Y., Xu, Y., Jiang, Z., Guo, M., & Teng, F. (2026) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2026.104859 · Cited by 1
Guo, J., Bachor, T. P., Takahashi, R., Steffek, M., Fitzgerald, G. A., Huffman, B. J., Braun, D., Han, S. J., Sandmann, T., Ha, C., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.10.06.680810 · Cited by 2
Khokhar, M., Yadav, D., & Sharma, P. (2026) · Indian Journal of Clinical Biochemistry · doi:10.1007/s12291-026-01417-5 · Cited by 1
Varma, G., Murugadoss, K., Kurian, M. E., Varghese, J., Venkatakrishnan, A., & Soundararajan, V. (2026) · Biology Methods and Protocols · doi:10.1093/biomethods/bpag035 · Cited by 3
Anker, S. D., Ji, L., Kindel, T. L., Coats, A. J. S., Ojji, D. B., Puente-Barragán, A., Rossing, P. R., Zieroth, S. R., Ahmad, S., Usman, S., et al. (2026) · Journal of the Association of Physicians of India · doi:10.59556/japi.74.1445 · Cited by 1
Seijas‐Amigo, J., Salgado‐Barreira, Á., Eiras, S., Arias-Rivas, S., Rodríguez-Carnero, G., Rodríguez‐Mañero, M., & González‐Juanatey, J. R. (2026) · European Heart Journal Open · doi:10.1093/ehjopen/oeag101 · Cited by 2
Ibsen, D. B., Kobayashi, R., Bruun, J. M., & Drouin‐Chartier, J. (2025) · American Journal of Clinical Nutrition · doi:10.1016/j.ajcnut.2025.07.040 · Cited by 1
Bajpai, J., Saxena, M., Agarwal, U., & Pradhan, A. (2025) · World Journal of Experimental Medicine · doi:10.5493/wjem.v15.i4.109762 · Cited by 1
Bellido, V., le Roux, C. W., Ekinci, E. I., Bjornstad, P., Frías, J. P., Giblin, K. A., Eyde, S., Park, S. Y., Ferro, J., Johnson, C., et al. (2026) · The Lancet · doi:10.1016/s0140-6736(26)01861-1 · Cited by 8
Pharmacological therapy in the obese patient: is it only a matter of fat loss?
Borghi, C., & Bragagni, A. (2026) · European Heart Journal Supplements · doi:10.1093/eurheartjsupp/suag029 · Cited by 1
Keng, C., Thor, S. M., Balasubramaniam, R., & Pretorius, F. (2025) · Cureus · doi:10.7759/cureus.99664 · Cited by 1
Incretin therapy and obesity: current and future pharmacologic possibilities
Moss, E., Hawk, K., Lollis, K., & Clements, J. N. (2026) · Canadian Journal of Physiology and Pharmacology · doi:10.1139/cjpp-2025-0151 · Cited by 3
Luca, M. D., Modestino, M. R., Alsergani, A. H., Gabriele, M., Galzerano, D., Mallardo, M., Saldamarco, L., Bossone, E., & Cittadini, A. (2026) · Current Problems in Cardiology · doi:10.1016/j.cpcardiol.2026.103328 · Cited by 4
Khan, I., Meenakshi, S., Abubakar, M., Kumar, N., Gaikwad, V. L., Rai, A., & Murti, K. (2026) · Endocrine · doi:10.1007/s12020-026-04686-5 · Cited by 2
Once-Monthly Maridebart Cafraglutide in Obesity — A Phase 2 Trial
Jastreboff, A. M., Ryan, D. H., & Pannacciulli, N. (2025) · New England Journal of Medicine · doi:10.1056/nejmc2514331 · Cited by 1
Mitropoulou, P., Prokšelj, K., Janež, A., Gil, F. R., Verma, S., Jurić, I., Vida, V. L., Gatzoulis, M. Α., & Brida, M. (2026) · European Heart Journal - Quality of Care and Clinical Outcomes · doi:10.1093/ehjqcco/qcag067 · Cited by 3
Exploring Weight Loss Medication Discourse: Mixed Methods Analysis of US-Based Facebook Posts
Dennard, E., Makres, K., Alibilli, A. S., Jain, V., Wang, A., Abim-Karmon, R., Criss, S., Hswen, Y., Nguyen, Q. C., Ratzki‐Leewing, A. A., et al. (2026) · JMIR Infodemiology · doi:10.2196/89732 · Cited by 4
Governor, S., Essien, E., Agyekum, A. K., Ahsan, A., Wiesel, S., Khurana, D., El‐Kersh, K., Altaee, O., Otchere, P., & Dávila‐Román, V. G. (2026) · medRxiv · doi:10.64898/2026.01.20.26344489 · Cited by 1
Lisco, G., Tullio, A. D., Disoteo, O., Dicorato, P., Tortora, A., Geronimo, V. D., & Triggiani, V. (2026) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-026-10033-w · Cited by 1
Lee, A. T., Park, C. H., Arter, Z., Nagasaka, M., & Ou, S.-H. (2025) · Lung Cancer Targets and Therapy · doi:10.2147/lctt.s549011 · Cited by 1
Levine, J., Lee, Y. A., Pham, A. K., Guo, J. S., Dai, H., Radwan, R. M., Bian, J., Novikov, A. A., & Sheer, A. (2025) · medRxiv · doi:10.1101/2025.11.13.25340005 · Cited by 2
Medical treatments for obesity: what does the future have in store?
Bassatne, A., & Rizo, I. M. (2026) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgag274 · Cited by 1
Unravelling obesity: from leptin to glucagon-like peptide-1 receptor agonists
Idowu, T. O., & Chmurzyńska, A. (2026) · Journal of Applied Genetics · doi:10.1007/s13353-026-01084-5 · Cited by 1
Semaglutide 7·2 mg: another step towards tackling diseases mediated by obesity
Sattar, N. A., & Lean, M. E. J. (2025) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(25)00262-1 · Cited by 1
Hussain, M., & Miras, A. D. (2025) · Die Chirurgie · doi:10.1007/s00104-025-02402-z · Cited by 3
Position Statement on Cardiometabolic Health Across the Woman's Life Course – 2025
de Oliveira, G. M. M., de Almeida, M. C. C., Valério, C. M., Giuffrida, F. M. A., Espíndola, L. N., Izar, M. C. D. O., Marques-Santos, C., Freire, C. M. V., Albuquerque, C. J. D. M., Chagas, A. C. P., et al. (2025) · Revista Brasileira Ginecologia e Obstetrícia · doi:10.61622/rbgo/2025rbgo200 · Cited by 2
Do, D., Murugiah, K., Sawano, M., et al. (2026) · JACC Advances · doi:10.1016/j.jacadv.2025.102575 · Cited by 2
Warden, B. A., Duell, P. B., Bucheit, J. D., & Purnell, J. Q. (2026) · Journal of clinical lipidology · doi:10.1016/j.jacl.2025.11.013 · Cited by 1
A new era in reducing obesity and the risk of cardiovascular disease events in preeclampsia
Malik, A., & Malik, R. A. (2026) · Journal of Hypertension · doi:10.1097/hjh.0000000000004250 · Cited by 1
GLP ‐1 Receptor Agonists for Treating Alcohol Use Disorder: A Critical Review
Woo, S., Zhu, G., Castro, C., Phuong, A., Roy, A., Davis, C. N., & Kranzler, H. R. (2026) · Alcoholism Clinical and Experimental Research · doi:10.1111/acer.70312 · Cited by 3
Metabolic Flux Adaptations During GLP-1 Receptor Agonist Therapy: Redox Implications
Lee, J., You, J. H., Park, H. J., Roh, J.-L., & Paek, S. H. (2026) · Current Obesity Reports · doi:10.1007/s13679-026-00709-4 · Cited by 3
Hamarsheh, S., Jaber, A. R., Abu-Khazneh, O., Andonie, C. R., Majadleh, S., Zahran, A., & Ayesh, H. (2026) · Endocrinology Diabetes & Metabolism · doi:10.1002/edm2.70248 · Cited by 2
Incretin Mimetics in Cancer and Cardiovascular Disease
Leong, D. P., Gong, S., Sattar, N. A., Narayan, V., Reizine, N. M., Gerstein, H. C., & Vellky, J. E. (2026) · JACC CardioOncology · doi:10.1016/j.jaccao.2025.12.003 · Cited by 3
GIPR:GCGR co-agonism restores normal weight in obese rodents
Pérez–Tilve, D., Zhang, F., Zhang, Y., Lohman, K., Sorrell, J. E., Vick, A., Müller, T. D., Tschoep, M. H., & DiMarchi, R. D. (2026) · Molecular Metabolism · doi:10.1016/j.molmet.2026.102365 · Cited by 1
Posicionamento sobre a Saúde Cardiometabólica ao Longo do Ciclo de Vida da Mulher – 2025
de Oliveira, G. M. M., de Almeida, M. C. C., Valério, C. M., Giuffrida, F. M. A., Espíndola, L. N., Izar, M. C. D. O., Marques-Santos, C., Freire, C. M. V., Albuquerque, C. J. D. M., Chagas, A. C. P., et al. (2025) · Arquivos Brasileiros de Cardiologia · doi:10.36660/abc.20250615 · Cited by 5
What obgyns need to know about GLP-1 receptor agonists
Chauhan, I. (2026) · Current Opinion in Obstetrics & Gynecology · doi:10.1097/gco.0000000000001116 · Cited by 1
Clift, A. K., Reisel, D., Johnson, H. H., Sattar, N. A., & Huang, D. R. (2026) · Journal of the Endocrine Society · doi:10.1210/jendso/bvag177 · Cited by 5
Song, S., Hyeon, M., Kim, S., Kang, Y., Hahm, S., Park, E. W., Shin, B. S., & Shin, S. (2026) · Journal of Analytical Science & Technology · doi:10.1186/s40543-026-00540-5 · Cited by 1
Incretin-Based Therapies, Obesity-Associated Inflammation, and Atherosclerotic Cardiovascular Risk
Kafol, J., Jug, B., & Fras, Z. (2026) · Cells · doi:10.3390/cells15141293 · Cited by 1
Murugadoss, K., Venkatakrishnan, A. J., & Soundararajan, V. (2026) · Preprints.org · doi:10.64898/2026.04.23.26351609 · Cited by 1
Efruxifermin in Compensated Liver Cirrhosis Caused by MASH
Noureddin, M., Shringarpure, R., & Yale, K. (2025) · New England Journal of Medicine · doi:10.1056/nejmc2510444 · Cited by 1
Impact of incretin analogues on lipid and lipoprotein metabolism in obesity and diabetes
Baragetti, A., & Norata, G. D. (2026) · British Journal of Pharmacology · doi:10.1111/bph.70483 · Cited by 2
Metadata
- Authors
- Aronne, L. J., Horn, D. B., le Roux, C. W., Ho, W., Falcon, B. L., Gomez Valderas, E., Das, S., Lee, C. J., Glass, L. C., Senyucel, C., & Dunn, J. P.
- Affiliations
- Weill Cornell Medicine (US)
- University of Texas Center for Obesity Medicine and Metabolic Performance, Department of Surgery, University of Texas McGovern Medical School, Houston
- Diabetes Complications Research Centre, Conway Institute, University College Dublin, Dublin
- University of California, Los Angeles (US)
- Eli Lilly, Indianapolis
- Eli Lilly (United States) (US)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2025-07-03
- Volume
- 393
- Issue
- 1
- Pages
- 26-36
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W4410277932
- Cited by
- 634
- References
- 40
- Citations by year
- 2026: 448 · 2025: 186
- FWCI
- 355.83
- Type
- journal article
- Language
- en
- Open access
- green
- hdl.handle.net
- Licence
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- eCommons (Cornell University) (submittedVersion, cc-by-nc-nd)
- Funders
- Eli Lilly and Company (NA)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Surgery › Bariatric Surgery and Outcomes
- Keywords
- tirzepatide, semaglutide, obesity, weight loss, waist circumference, GLP-1 receptor agonists, GIP/GLP-1 receptor agonist, gastrointestinal adverse effects, non-diabetic obesity
- MeSH terms
- Glucagon-Like Peptide-1 Receptor Agonists, Tirzepatide, Semaglutide, Adult, Aged, Body Weight, Female, Humans, Injections, Subcutaneous, Male, Middle Aged, Obesity, Weight Loss, Treatment Outcome, Anti-Obesity Agents, Maximum Tolerated Dose, Glucagon-Like Peptide 1, Waist Circumference
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.